Related Experiment Video
Updated: Jul 18, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Adalimumab therapy for recalcitrant pyoderma gangrenosum
Margaret A Fonder1, Deborah L Cummins, Benjamin D Ehst
1Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Journal of Burns and Wounds
|December 7, 2006
Summary
This case report details a patient with severe pyoderma gangrenosum unresponsive to multiple treatments. Adalimumab, a TNF-alpha inhibitor, successfully resolved ulcers, offering a novel therapeutic option for this challenging skin condition.
Area of Science:
- Dermatology
- Immunology
- Gastroenterology
Background:
- Pyoderma gangrenosum (PG) is a rare, ulcerative neutrophilic dermatosis often associated with systemic diseases.
- Treatment-refractory PG poses a significant clinical challenge, necessitating exploration of novel therapeutic strategies.
Purpose of the Study:
- To report a case of severe pyoderma gangrenosum refractory to conventional therapies.
- To evaluate the efficacy of adalimumab, a tumor necrosis factor-alpha (TNF-alpha) inhibitor, in managing treatment-resistant pyoderma gangrenosum.
Main Methods:
- A comprehensive literature review was conducted.
- A detailed case report of a patient with inflammatory bowel disease and refractory pyoderma gangrenosum is presented.
Main Results:
- The patient developed severe pyoderma gangrenosum despite treatment with infliximab, a chimeric anti-TNF-alpha antibody.
- Numerous immunosuppressive and immunomodulatory agents failed to induce remission.
- Ulcerative lesions resolved completely following the initiation of adalimumab, a fully humanized anti-TNF-alpha monoclonal antibody.
Conclusions:
- Adalimumab represents a novel and effective therapeutic option for refractory pyoderma gangrenosum.
- Targeting TNF-alpha with adalimumab may be beneficial in managing severe cases of pyoderma gangrenosum, particularly in patients with underlying inflammatory conditions.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...